RMI is a subsidiary of RUSNANO JSC created in 2012 for the implementation of innovative projects in the field of medicine and pharmaceuticals.About us
We are interested in cooperation with the authors of new promising ideas in the field of pharmaceuticals and medical equipment.Portfolio
Rusnano and Domain have made an agreement on joint investments in pharmaceuticals and medical development for innovation.About agreement
RMI is a subsidiary of RUSNANO JSC created in 2012 for the implementation of innovative projects in the field of medicine and pharmaceuticals.Our history
RMI was created in March 2012.
Initial funding - $380 million.
The RusnanoMedInvest fund was established by RUSNANO, the nanotechnology investment, research and development arm of the Russian Government together with Domain Associates LLC, one of the premier U.S. life sciences technology venture investment firms. The RusnanoMedInvest fund seeks, in addition to securing differentiated and sustainable returns to its investment portfolio, to promote the following social and developmental objectives in Russia
NovaMedica, a Russian pharmaceutical company, is starting construction of R&D Center for innovative drug development and pilot production in Moscow. This Center will include laboratories and production areas equipped with state-of-the-art process equipment that has never been used in the Russian pharmaceutical industry before. The total investments are estimated approximately $15 million.
30 June 2016
30 June 2016